Neuroimaging Sample Clauses

Neuroimaging. The ability to perform brain imaging studies on acute stroke patients is vital for physicians to make a fast, accurate diagnosis of stroke patients. Brain imaging studies include CT scans. A Primary Stroke Center must be capable of performing an imaging study within twenty-five (25) minutes of a physician's order. The image shall be evaluated by a physician within twenty (20) minutes of completion.
AutoNDA by SimpleDocs
Neuroimaging. Neuroimaging techniques have added to our knowledge of which brain structures are active during the experience of nocebo effects. Again studies in the pain field have tended to show that nocebo effects are mediated by the hippocampus and regions involved in anticipatory anxiety processing. Xxxx et al. (2008) compared functional magnetic resonance imaging responses following thermal stimuli of equal intensity delivered at control sites or at nocebo sites (where participants were conditioned or told to expect pain) on participants’ right forearms. Increased pain reports for the nocebo sites were associated with increased activity in the medial pain matrix, which included the bilateral dorsal anterior cingulate cortex, insula, left frontal and parietal operculum, orbitofrontal cortex, and hippocampus. In a subsequent study that investigated the influence of expectancy on the analgesic effect of remifentanil, Xxxxxx et al. (2011) found that positive expectancy effects were associated with activity in the endogenous pain modulatory system, and negative expectancy effects with activity in the hippocampus, suggesting different mechanisms underlying placebo and nocebo effects. However Xxxxx et al. (2008) found an overlapping network. In this study, placebo responding to a 20 minute pain challenge was associated with enhanced opioid neurotransmission in the anterior cingulate, orbitofrontal and insular cortex, nucleus accumbens, amygdala, and periaqueductal gray, as well as DA in the ventral basal ganglia, including the nucleus accumbens. Nocebo responding was associated with the opposite changes in brain activity: a decrease of DA, and decreased opioid release in those brain regions. Endogenous opioids and DA have also been identified as neurochemical systems involved in nocebo responses (Xxxxxx, Xxxxxxx, & Xxxxxxxx, 2016), as highlighted previously. Studies that directly compare the placebo and nocebo effects using the same cohort of subjects may help provide a general model of how different expectancies can modulate brain responses. Xxxxxxx et al. (2015) manipulated subjects' treatment expectation of the effectiveness of different inert creams administered before noxious stimuli and found that the expectation of an increase in pain induced significant activity in the insula, orbitofrontal cortex, and periaqueductal gray, whereas the expectation of pain relief evoked significant activity in the striatum. There were no brain regions which were common to both posit...
Neuroimaging. Functional magnetic resonance imaging (fMRI) has been used since 1991 to measure hemodynamic responses in the brain (Xxxxx et al., 1992). Blood-oxygen-level-dependant (BOLD) contrast is used to visualize blood flow throughout the brain. An increase in neural activity causes a change in the ratio of deoxygenated hemoglobin to oxygenated hemoglobin, which is detected by the fMRI scanner. This process produces a T2* weighted image, which has poor spatial resolution. The T1-weighted image is collected by measuring the rate at which protons align and spin after being exposed to a magnetic pulse at a specific radio frequency (Damadian, Goldsmith, & Minkoff, 1977). This MRI image shows the detailed, anatomical structure of the brain, but does not show any functional activation. The two images are then superimposed and co-registered to better identify the locations of changes in BOLD signal from the T2* images using the anatomically detailed T1 image (further discussion in Methods section). Although BOLD signal should not be confused with the actual firing of neurons, several studies have shown similarities in function between areas implicated by fMRI and lesion studies (Gaillard et al., 2006; Menon & Xxxxxxx, 0000; Saygin, 2007). Voxel-based morphometry (VBM) is a method to measure grey matter volume using the T1 weighted MRI image. A voxel is a volumetric pixel that represents a value in 3D space. The images are first registered to a standard brain and smoothed to allow for comparison between subjects (Ashburner & Friston, 2000). Grey matter density is then compared across subjects (Ashburner & Friston, 2000). Neuroanatomical features are highly heritable, as demonstrated in twin studies (Xxxxxx, Sham, Murray, Weinberger, & Bullmore, 2002). Cooperative behavior could be motivated by the rewarding feeling of doing good for others or the negative feeling from non-cooperative behavior. How either of these motivations are processed in the brain is of interest to this study and can be illuminated when one considers the neural response to other rewarding or negative stimuli. Using fMRI and VBM, several brain structures have been implicated in reward processing. These structures include the medial orbitofrontal cortex (mOFC), amygdala, and nucleus accumbens (NAc), which are activated by rewards such as sexual activity and food (XxXxxxx, York, & Montague, 2004). Social rewards, such as beautiful faces (Aharon et al., 2001) and cooperation (Xxxxxxx et al., 2002), have be...
Neuroimaging. Two assessments will be needed for each animal: the first just prior to implantation of the Microbot device to determine the extent of ventriculomegaly and the second just prior to termination of the experiment to determine the effectiveness of the device. As described under “Animals”, fewer studies may be conducted if the objectives have been met. Furthermore, if ultrasonography can be shown to accurately determine the extent of ventriculomegaly then the CT scans will not be needed. However, if CT scans are needed, then transportation and veterinary care expenses will be incurred as required by the IACUC protocol.

Related to Neuroimaging

  • Technology Discoveries, innovations, Know-How and inventions, whether patentable or not, including computer software, recognized under U.S. law as intellectual creations to which rights of ownership accrue, including, but not limited to, patents, trade secrets, maskworks and copyrights developed under this Agreement.

  • Manufacturing (a) The Supplier shall without limitation be responsible, at no additional cost to the Purchaser, for: sourcing and procuring all raw materials for the Products; obtaining all necessary approvals, permits and licenses for the manufacturing of the Products; providing sufficient qualified staff and workers to perform the obligations under this Purchase Agreement; implementing and maintaining effective inventory and production control procedures with respect to the Products; and handling other matters as reasonably requested by the Purchaser from time to time.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Collaboration Management Promptly after the Effective Date, each Party will appoint a person who will oversee day-to-day contact between the Parties for all matters related to the management of the Collaboration Activities in between meetings of the JSC and will have such other responsibilities as the Parties may agree in writing after the Effective Date. One person will be designated by Merck (the “Merck Program Director”) and one person will be designated by Moderna (the “Moderna Program Director,”) together will be the “Program Directors”. Each Party may replace its Program Director at any time by notice in writing to the other Party. Any Program Director may designate a substitute to temporarily perform the functions of that Program Director by written notice to the other Party. The initial Program Directors will be: For Moderna: [***] For Merck: [***]

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Formation; Composition Within […***…] days after the Effective Date, the Parties shall establish a committee to oversee Development of Licensed Product(s) in the Territory in accordance with the Development Plan(s) for the same and to coordinate the Development activities of the Parties, and review and discuss the Development and Manufacture of Licensed Compound and Licensed Products (the “JDC”). Each Party shall initially appoint three (3) representatives to the JDC, with each representative having knowledge and expertise in the development of compounds and products similar to the Licensed Products and having sufficient seniority within the applicable Party to make decisions arising within the scope of the JDC’s responsibilities. The JDC may change its size from time to time if agreed by consensus among its members, provided that the JDC shall consist at all times of an equal number of representatives of each of Galapagos and Gilead. Each Party may replace its JDC representatives at any time upon written notice to the other Party. The JDC may invite non-members to participate in the discussions and meetings of the JDC, provided that such participants shall have no voting authority at the JDC. The JDC shall have a chairperson, who shall serve for a term of one (1) year, and who shall be selected alternately, on an annual basis, by Galapagos or Gilead. The initial chairperson shall be selected by […***…]. The role of the chairperson shall be to convene and preside at meetings of the JDC and to ensure the preparation of minutes, but the chairperson shall have no additional powers or rights beyond those held by the other JDC representatives.

  • Development Services During the term of this Agreement, the Provider agrees to provide to or on behalf of the Port the professional services and related items described in Exhibit A (collectively, the “Development Services”) in accordance with the terms and conditions of this Agreement. The Provider specifically agrees to include at least one Port representative in any economic development negotiations or discussions in which the Provider is involved concerning (i) a port-related business prospect or (ii) a business transaction which will ultimately require Port involvement, financial or otherwise.

  • Product Development Attach all requested documentation and attach additional pages as necessary. For all requirements include efforts of all Sublicensees. If not applicable, please so indicate by N/A.

  • Stability 14.01 Maintain a documented, ongoing stability program to monitor the stability of the Product using stability indicating procedures. X 14.02 Data analysis and trending reporting will be performed. X

  • Research Support opioid abatement research that may include, but is not limited to, the following:

Time is Money Join Law Insider Premium to draft better contracts faster.